Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial

Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial

Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT).Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021. The participants received avatrombopag tablets 60 mg once a day...

Full description

Bibliographic Details
Main Authors: Yayun Cui, Yifu He, Changlu Hu, Congyin Tu, Jin Huang, Xiaofeng Zhu, Chunbao Zang, Kaiyang Ding, Bihong Zhan, Yufei Zhao, Liting Qian
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
chemotherapy
adverse event
thrombocytopenia
receptors
thrombopoietin
agonist
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.970978/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.970978/full

Similar Items